Novo Nordisk to Launch Wegovy Vials Amid Price War

Novo Nordisk A/S is preparing to launch Wegovy in vial form, a significant step to enhance its competitiveness against rival Eli Lilly & Co. The company intends to introduce these vials in the US this year, with subsequent rollouts in other international markets. This strategic expansion aims to broaden the drug's accessibility and appeal to a wider patient base.

The introduction of vials offers patients more flexible dosing options, a feature that has proven popular with Eli Lilly's offerings. Lilly began selling vials of its weight-loss drug in 2024, a move that also helped alleviate supply shortages. These vials, available through Lilly's direct-to-consumer platform, now constitute a substantial portion of new patients starting weight-loss medications.

Novo Nordisk is also implementing significant price cuts across its obesity drug portfolio to attract more patients and reclaim market share. The company is offering its Wegovy pill directly to consumers at a reduced price. Despite these efforts to boost sales volume, these aggressive discounts are projected to cause a sales decline of up to 13% for Novo Nordisk this year.